{"member_organisations": "http://www.ipha.ie/alist/member-companies.aspx", "identification_number": "701937518594-20", "fields_of_interest": "Public Health", "head_office_address": "Wilton Park House Wilton Place", "full_time_equivalent_fte": "0,25", "person_with_legal_responsibility": "Oliver O'Connor", "inter_groups": "", "financial_year_start_date": "01/01/2017", "grants": "", "head_office_country": "Ireland", "eu_initiatives": "We track all EU polices of relevance to our business in the areas of regulation, access and pricing of innovative medicines.", "organisation_name": "Irish Pharmaceutical Healthcare Association (IPHA)", "belgium_office_post_code": "", "number_of_persons_involved": "1", "procurement": "", "section": "II - In-house lobbyists and trade/business/professional associations", "source": "", "belgium_office_address": "", "subsection": "Trade and business associations", "belgium_office_phone": "", "number_of_ep_accredited_persons": "", "overall_budget_turnover_as_a_range": "", "belgium_office_city": "", "persons_accredited_for_access_to_european_parliament_premises": "", "estimate_of_costs_absolute_amount": "0", "registration_date": "31/08/2015", "website_address": "http://www.ipha.ie", "commission_expert_groups_and_other_similar_entities_european_commission": "NA", "head_office_post_box": "", "head_office_city": "Dublin 2", "membership": "We are members of EFPIA and AESGP", "head_office_post_code": "", "goals__remit": "The Irish Pharmaceutical Healthcare Association (IPHA) represents the international research based pharmaceutical industry in Ireland. Our members include both manufacturers of prescription medicines and non-prescription or consumer health care medicines. \n \nThe mission of IPHA is to create a favourable economic, regulatory and political environment, which will enable the research-based pharmaceutical industry in Ireland to meet the growing healthcare needs and expectations of patients.  \n \nIt aims also to develop an appreciation of the value of medicines, in particular innovative medicines, to healthcare and society as a whole thereby ensuring patients' continued, timely access to the full range of available medicines, regardless of their ability to pay.", "industry_forums": "", "head_office_phone": "(+3531)6610018", "level_of_interest": "national", "relevant_communication": "We are active in communicating the industry's position on the proposed EC SPC manufacturing waiver. As members of IMVO, we are preparing for the implementation of the Falsified Medicines Directive.", "financial_year_end_date": "01/12/2017", "estimate_of_costs_as_a_range": "", "overall_budget_turnover_absolute_amount": "0", "legal_status": "Association", "person_in_charge_of_eu_relations": "Oliver O'Connor", "customers": "", "belgium_office_post_box": "", "position": "Chief Executive Officer"}